Niosomal Formulation Studies to Overcome Reduced Bioavailability of Antifungal Agent Griseofulvin

Description

Griseofulvin, an antifungal drug used to treat dermatophyte infections, exhibits poor aqueous solubility and low bioavailability (25–70%), classified as a Biopharmaceutics Classification System (BCS) Class II drug. This limits its therapeutic efficacy and necessitates high doses, increasing the risk of side effects such as gastrointestinal distress and hepatotoxicity. Niosomes, non-ionic surfactant-based vesicles, offer a promising drug delivery system due to their ability to encapsulate hydrophobic drugs, enhance solubility, and improve bioavailability through controlled release and enhanced membrane penetration. This research proposes to develop and evaluate niosomal formulations to overcome the reduced bioavailability of Griseofulvin, aiming to improve its clinical efficacy and patient compliance.